Oncology
Revealing the molecular mechanism of tumor development and identifying the matching inhibitory candidates is one important area within the cancer research.
The tumor diversity is extremely high. Therefore, cancer research belongs to the high variant research areas with manifold scientific approaches.
To match this challenge, we offer you a unique diversity of products for your oncology research and development in the academic and pharmaceutical field.
Click on the organs and learn more about cancer types
General information
Oncologists focus on the diagnosis, therapy and follow-up of cancer.
Cancer is a class of diseases in which cells start to divide uncontrollably and invade other tissues. Cancer cells can spread to other parts of the body via the blood and lymphatic system. Under physiological conditions, cell proliferation is tightly controlled by many mechanisms. In addition, the immune system is able to recognize and destroy cancer cells. If these mechanisms fail or the immune system cannot effectively destroy the cells, it can lead to a malignant tumor. Theoretically, a malignant neoplasm can occur everywhere, but there are cancers that are more often than others. For men it is the prostate and in women it is the mammary gland.
Relevant products for oncology research
| Name | Price | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Anti-B7-H1 / PD-L1 / CD274 Reference Antibody (durvalumab) | Login | Anti-B7-H1 / PD-L1 / CD274 Reference Antibody (durvalumab) | ||||||||||||||||
|
||||||||||||||||||
| Anti-FGF23 Reference Antibody (burosumab) | Login | Anti-FGF23 Reference Antibody (burosumab) | ||||||||||||||||
|
||||||||||||||||||
| Anti-PDCD1 / PD-1 / CD279 Reference Antibody (budigalimab) | Login | Anti-PDCD1 / PD-1 / CD279 Reference Antibody (budigalimab) | ||||||||||||||||
|
||||||||||||||||||
| Anti-CD4 Reference Antibody (tregalizumab) | Login | Anti-CD4 Reference Antibody (tregalizumab) | ||||||||||||||||
|
||||||||||||||||||
| Anti-TNFSF5 / CD40L / CD154 Reference Antibody (letolizumab) | Login | Anti-TNFSF5 / CD40L / CD154 Reference Antibody (letolizumab) | ||||||||||||||||
|
||||||||||||||||||
| Anti-NaPi2b / SLC34A2 Reference Antibody (Lifastuzumab) | Login | Anti-NaPi2b / SLC34A2 Reference Antibody (Lifastuzumab) | ||||||||||||||||
|
||||||||||||||||||
| Anti-TNFRSF4 / OX40 / CD134 Reference Antibody (BMS-986178) | Login | Anti-TNFRSF4 / OX40 / CD134 Reference Antibody (BMS-986178) | ||||||||||||||||
|
||||||||||||||||||
| Anti-Integrin a5b1 (ITGA5 & ITGB1) Reference Antibody (volociximab) | Login | Anti-Integrin a5b1 (ITGA5 & ITGB1) Reference Antibody (volociximab) | ||||||||||||||||
|
||||||||||||||||||
| Anti-ICAM1 / CD54 Reference Antibody (bersanlimab) | Login | Anti-ICAM1 / CD54 Reference Antibody (bersanlimab) | ||||||||||||||||
|
||||||||||||||||||
| Anti-PDCD1 / PD-1 / CD279 Reference Antibody (ezabenlimab) | Login | Anti-PDCD1 / PD-1 / CD279 Reference Antibody (ezabenlimab) | ||||||||||||||||
|
||||||||||||||||||
| Anti-AXL / UFO Reference Antibody (mipasetamAb) | Login | Anti-AXL / UFO Reference Antibody (mipasetamAb) | ||||||||||||||||
|
||||||||||||||||||
| Anti-TNFRSF17 / BCMA / CD269 Reference Antibody (belantamab mafodotin) | Login | Anti-TNFRSF17 / BCMA / CD269 Reference Antibody (belantamab mafodotin) | ||||||||||||||||
|
||||||||||||||||||
| Anti-TNFRSF17 / BCMA / CD269 Reference Antibody (belantamab) | Login | Anti-TNFRSF17 / BCMA / CD269 Reference Antibody (belantamab) | ||||||||||||||||
|
||||||||||||||||||
| Anti-CTLA-4 / CD152 Reference Antibody (nurulimab) | Login | Anti-CTLA-4 / CD152 Reference Antibody (nurulimab) | ||||||||||||||||
|
||||||||||||||||||
| Anti-PTPRC / CD45 Reference Antibody (apamistamab) | Login | Anti-PTPRC / CD45 Reference Antibody (apamistamab) | ||||||||||||||||
|
||||||||||||||||||
| Anti-LYPD3 / C4.4A Reference Antibody (lupartumab) | Login | Anti-LYPD3 / C4.4A Reference Antibody (lupartumab) | ||||||||||||||||
|
||||||||||||||||||
| Anti-TNFRSF4 / OX40 / CD134 Reference Antibody (ivuxolimab) | Login | Anti-TNFRSF4 / OX40 / CD134 Reference Antibody (ivuxolimab) | ||||||||||||||||
|
||||||||||||||||||
| Anti-AXL / UFO Reference Antibody (enapotamab vedotin) | Login | Anti-AXL / UFO Reference Antibody (enapotamab vedotin) | ||||||||||||||||
|
||||||||||||||||||
| Anti-VEGFR2 / KDR / CD309 Reference Antibody (AT001) | Login | Anti-VEGFR2 / KDR / CD309 Reference Antibody (AT001) | ||||||||||||||||
|
||||||||||||||||||
| Anti-TGFb1 Reference Antibody (Metelimumab) | Login | Anti-TGFb1 Reference Antibody (Metelimumab) | ||||||||||||||||
|
||||||||||||||||||
| Anti-TGFb1 Reference Antibody (NIS793) | Login | Anti-TGFb1 Reference Antibody (NIS793) | ||||||||||||||||
|
||||||||||||||||||
| Anti-TNFSF5 / CD40L / CD154 Reference Antibody (Toralizumab) | Login | Anti-TNFSF5 / CD40L / CD154 Reference Antibody (Toralizumab) | ||||||||||||||||
|
||||||||||||||||||
| Anti-MIF Reference Antibody (imalumab) | Login | Anti-MIF Reference Antibody (imalumab) | ||||||||||||||||
|
||||||||||||||||||
| Anti-IGF1R / CD221 Reference Antibody (figitumumab) | Login | Anti-IGF1R / CD221 Reference Antibody (figitumumab) | ||||||||||||||||
|
||||||||||||||||||
| Anti-IGF1R / CD221 Reference Antibody (dalotuzumab) | Login | Anti-IGF1R / CD221 Reference Antibody (dalotuzumab) | ||||||||||||||||
|
||||||||||||||||||


